Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma.

Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma.

Treatment of metastatic malignant melanoma patients harboring BRAF(V600E) has improved drastically after the discovery of the BRAF inhibitor, vemurafenib. However, drug resistance is a recurring problem, and prognoses are still very bad for patients harboring BRAF wild-type. Better markers for targe...

Full description

Bibliographic Details
Main Authors: Andliena Tahiri, Kathrine Røe, Anne H Ree, Rik de Wijn, Karianne Risberg, Christian Busch, Per E Lønning, Vessela Kristensen, Jürgen Geisler
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3758344?pdf=render

Internet

http://europepmc.org/articles/PMC3758344?pdf=render

Similar Items